Liquidia Corporation (LQDA) Settles With UTHR; Pays $380.7M, Keeps YUTREPIA in PAH
Liquidia (LQDA) settled with United Therapeutics, paying $380.7M in installments by 2027. The deal resolves all lawsuits, allows continued YUTREPIA sales for PAH, and removes PH-ILD from its label. LQDA reported $222.7M in Q3'26 YUTREPIA sales, with $396.1M in cash as of September 30, 2026.
How this was made
The 30-second read
Why it matters
The settlement removes legal overhang but imposes a sizable cash burden, likely creating short‑term downside pressure while preserving long‑term product revenue.
Market read
First disclosure of a multi‑hundred‑million settlement for a mid‑cap biotech; material for traders evaluating cash‑flow risk.
What to watch
Strong Q3 YUTREPIA sales ($222.7M) may offset cash outflow concerns and support the share price.
Background
Liquidia resolves six lawsuits with United Therapeutics, pays $380.7M in installments, and maintains YUTREPIA availability for PAH patients.
Ticker impact
Liquidia announced a $380.7M settlement with United Therapeutics, detailing payment schedule and confirming continued YUTREPIA sales for PAH.
downside pressure as the market prices in the large cash payment schedule
Settlement amount is material for a mid‑cap biotech; cash outflow reduces liquidity and may trigger short‑term sell‑off.
Market effects
Biotech firms with pending litigation may see heightened scrutiny; investors may reassess risk of legal exposures.
U.S. biotech sector could face modest pullback as settlement news spreads.
Limited to companies with similar antitrust or IP disputes; no broad macro effect.
Counterpoint
If the settlement clears legal uncertainty, the stock could rally on reduced risk and continued product sales.
Key entities
- CompanyLiquidia Corporation
Biopharma developing YUTREPIA for pulmonary arterial hypertension.
- CompanyUnited Therapeutics
Counterparty in the antitrust settlement.